Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Splisense
company
About
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
- Jerusalem,Yerushalayim,Israel
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $28.50M
- Industries
- Biotechnology,Life Science,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Legal Name
- Splisense Ltd.
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$28.50M
Splisense has raised a total of
$28.50M
in funding over 2 rounds. Their latest funding was raised on
May 13, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 13, 2021 | Series B | $28.50M | 5 |
Cystic Fibrosis Foundation
|
— | Detail |
| Jan 1, 2016 | Seed | — | 1 |
Integra Holdings
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
5
Splisense is funded by 5 investors.
Cystic Fibrosis Foundation
and Biotel
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Cystic Fibrosis Foundation
|
Yes | Series B |
|
|
— | Series B |
|
Integra Holdings
|
— | Series B |
Israel Biotech Fund
|
— | Series B |
OrbiMed
|
— | Series B |
Employee Profiles
Number of Employee Profiles
3
Splisense has 3 current employee profiles, including
Executive Dr. Gili Hart
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
